Praxis Precision Medicines (NASDAQ:PRAX – Free Report) had its price target increased by JPMorgan Chase & Co. from $700.00 to $725.00 in a report published on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.
A number of other brokerages also recently weighed in on PRAX. Wall Street Zen downgraded shares of Praxis Precision Medicines from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. B. Riley Financial initiated coverage on Praxis Precision Medicines in a report on Friday. They issued a “buy” rating and a $713.00 price target on the stock. Guggenheim increased their price objective on Praxis Precision Medicines from $800.00 to $1,050.00 and gave the company a “buy” rating in a research report on Monday, November 16th. Wells Fargo & Company set a $509.00 price objective on Praxis Precision Medicines and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Robert W. Baird raised their price objective on Praxis Precision Medicines from $514.00 to $568.00 and gave the stock an “outperform” rating in a research note on Monday, November 16th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $660.50.
Check Out Our Latest Analysis on PRAX
Praxis Precision Medicines Stock Down 3.4%
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($3.23) EPS for the quarter, beating analysts’ consensus estimates of ($3.54) by $0.31. On average, equities analysts expect that Praxis Precision Medicines will post -13.72 EPS for the current year.
Institutional Trading of Praxis Precision Medicines
Several institutional investors have recently made changes to their positions in PRAX. Seven Fleet Capital Management LP acquired a new stake in shares of Praxis Precision Medicines in the second quarter worth $2,524,000. Readystate Asset Management LP bought a new stake in shares of Praxis Precision Medicines during the 2nd quarter worth $3,531,000. Swiss National Bank boosted its holdings in shares of Praxis Precision Medicines by 15.3% during the 1st quarter. Swiss National Bank now owns 46,700 shares of the company’s stock worth $15,046,000 after buying an additional 6,200 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Praxis Precision Medicines in the 2nd quarter valued at $2,698,000. Finally, Orbimed Advisors LLC increased its stake in shares of Praxis Precision Medicines by 82.5% in the first quarter. Orbimed Advisors LLC now owns 172,500 shares of the company’s stock worth $55,578,000 after purchasing an additional 78,000 shares during the period. 67.84% of the stock is currently owned by institutional investors and hedge funds.
Praxis Precision Medicines Company Profile
Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.
See Also
- Five stocks we like better than Praxis Precision Medicines
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
